Saturday, June 19, 2021 8:15:30 AM
Red, IMO, this is how it will go down.
1) As the efficacy of Anavex's drugs are understood (it only takes the understanding of one drug's MoA to realize the power of the other "family" members), one of the Consortium (Merck and/or Takeda) will bring together 5-8 other BP to digest what the future will be like if Anavex continues to advance forward.
2) Once that realization sets in, i.e., the revenues of BP declines by 70-80% within 10 years, BP decides to react.
3) The question it faces is: Do they split Anavex up for each firm's particular interest or do the companies decide to "Deep Six" all of Anavex drugs?
4) If they act on the former, i.e., acting like a cabal, the SP offered will be lower than if BP wants to terminate the pipeline ... think Keystone. If it were the later, the offer must be overwhelming to get the necessary shares.
5) BP will attempt to move before Anavex receives approval (not disclosure of the results) at any level.
6) This is likely to happen before the end of 2022 as long as BP can thwart/delay any approval by TGA et al.
P.S. I believe when there are significant "technological breakthroughs" looming, American/European business do not play fair, but will do everything in its power to prevent that transformational event from happening.
I am on the same page w/youze guys. Have witnessed while medical docs/records got shredded to cover issues of international consequence. Shocked me but learned it goes on all the time. EU in particular and Asia. No one should be surprised that many have no problem telling medical -clinical untruths, making it up as they go.
THIS IS GONNA BE (maybe already is) HARDBALL. AVXL has set up a sequence of WW actions which is not stoppable (unless it is stopped) in the natural flow of natural solutions must prevail. BP WW and all related finance/medical worlds are about to be nuked and some can see it coming. I hope Dr.M. has a food taster on staff.
IMO, using Precision Medicine and AI AVXL is pushing the BP world to carefully assess how their respective products and the human consequences of their use are literally unknown or incompletely understood and may be toxic in many evolutionary circumstances.
Actually, stealth makes a lot of sense if this is going the way it looks right now.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
